Skip to main content

Conference Coverage

Conference Coverage
11/15/2023
Dr Paras Karmacharya discusses the findings of the PsA Research Consortium (PARC) cohort study that underscores the need for personalized treatment approaches in psoriatic arthritis, accounting for unique disease features.
Dr Paras Karmacharya discusses the findings of the PsA Research Consortium (PARC) cohort study that underscores the need for personalized treatment approaches in psoriatic arthritis, accounting for unique disease features.
Dr Paras Karmacharya discusses...
11/15/2023
Autoimmune
Conference Coverage
11/13/2023
Research presented at ACR Convergence assessed the impact of social determinants of health on patients with rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus.
Research presented at ACR Convergence assessed the impact of social determinants of health on patients with rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus.
Research presented at ACR...
11/13/2023
Rheumatology & Arthritis
Conference Coverage
11/13/2023
Dr Proton Rahman identified factors driving disagreement between patients and physicians analyzing the data from more than 1000 participants.
Dr Proton Rahman identified factors driving disagreement between patients and physicians analyzing the data from more than 1000 participants.
Dr Proton Rahman identified...
11/13/2023
Rheumatology & Arthritis
Conference Coverage
11/13/2023
A study conducted in France revealed significant differences in how strongly the sexes adhered to therapies for psoriatic arthritis.
A study conducted in France revealed significant differences in how strongly the sexes adhered to therapies for psoriatic arthritis.
A study conducted in France...
11/13/2023
Rheumatology & Arthritis
Conference Coverage
11/12/2023
A new combined clinical-genetic risk score has demonstrated superiority to clinical risk factors alone for diagnosing interstitial lung disease (ILD) among patients with rheumatoid arthritis (RA).
A new combined clinical-genetic risk score has demonstrated superiority to clinical risk factors alone for diagnosing interstitial lung disease (ILD) among patients with rheumatoid arthritis (RA).
A new combined clinical-genetic...
11/12/2023
Rheumatology & Arthritis
Conference Coverage
11/12/2023
Dr George Karpouzas explained how biologic therapies may protect against major cardiovascular events among patients with rheumatoid arthritis.
Dr George Karpouzas explained how biologic therapies may protect against major cardiovascular events among patients with rheumatoid arthritis.
Dr George Karpouzas explained...
11/12/2023
Rheumatology & Arthritis
Conference Coverage
11/12/2023
Dr Kristin Wipfler reviews data from the FORWARD biobank on the need for more research into the refractory phenotype of rheumatoid arthritis.
Dr Kristin Wipfler reviews data from the FORWARD biobank on the need for more research into the refractory phenotype of rheumatoid arthritis.
Dr Kristin Wipfler reviews data...
11/12/2023
Rheumatology & Arthritis
Conference Coverage
11/12/2023
Can digital health tools offer more insight outside of clinical setting in the treatment of rheumatoid arthritis? Dr Shilpa Venkatachalam spoke on the topic at ACR Convergence.
Can digital health tools offer more insight outside of clinical setting in the treatment of rheumatoid arthritis? Dr Shilpa Venkatachalam spoke on the topic at ACR Convergence.
Can digital health tools offer...
11/12/2023
Rheumatology & Arthritis
Lihi Eder, MD
Conference Coverage
08/14/2023
Dr Eder, from the University of Toronto, presented a poster at ACR Convergence on research that sheds light into how metabolic disorders and abnormal dietary patterns affect psoriatic arthritis disease activity.
Dr Eder, from the University of Toronto, presented a poster at ACR Convergence on research that sheds light into how metabolic disorders and abnormal dietary patterns affect psoriatic arthritis disease activity.
Dr Eder, from the University of...
08/14/2023
Rheumatology & Arthritis
Joseph Merola
Conference Coverage
07/19/2023
Dr Merola and colleagues conducted a post hoc analysis of the KEEPsAkE 1 and 2 trials of risankizumab among patients with active psoriatic arthritis to evaluates patient subgroups at 52 weeks of treatment.
Dr Merola and colleagues conducted a post hoc analysis of the KEEPsAkE 1 and 2 trials of risankizumab among patients with active psoriatic arthritis to evaluates patient subgroups at 52 weeks of treatment.
Dr Merola and colleagues...
07/19/2023
Rheumatology & Arthritis